125.98
Repligen Corp stock is traded at $125.98, with a volume of 382.40K.
It is up +2.27% in the last 24 hours and down -13.87% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$123.06
Open:
$123.86
24h Volume:
382.40K
Relative Volume:
0.55
Market Cap:
$7.09B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-406.40
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-4.76%
1M Performance:
-13.87%
6M Performance:
+4.37%
1Y Performance:
-18.71%
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RGEN
Repligen Corp
|
125.81 | 6.93B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
500.96 | 176.65B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.23 | 49.56B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.90 | 40.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
258.36 | 37.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
43.28 | 36.02B | 28.43B | 1.16B | 1.26B | 1.4457 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Repligen Corporation $RGEN Shares Sold by TD Asset Management Inc - MarketBeat
NZS Capital LLC Has $26.30 Million Stake in Repligen Corporation $RGEN - MarketBeat
Repligen (RGEN) COO uses 3,911 shares to cover tax withholding - Stock Titan
Repligen (RGEN) CEO reports tax-withholding share dispositions in Form 4 - Stock Titan
Repligen (RGEN) director uses 9,897 shares to cover RSU taxes - Stock Titan
Repligen (RGEN) CFO stock withheld to cover RSU tax obligations - Stock Titan
Repligen (RGEN) SVP uses company shares to cover RSU taxes - Stock Titan
Repligen (RGEN) CPO has shares withheld to cover RSU tax bill - Stock Titan
Repligen Corporation (RGEN) Investor Outlook: Exploring a 44.7% Potential Upside in the Bioprocessing Sector - DirectorsTalk Interviews
Repligen Corporation $RGEN Position Boosted by Royce & Associates LP - MarketBeat
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead - Finviz
Artisan Partners Limited Partnership Has $28.44 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Primecap Management Co. CA Has $24.98 Million Stock Position in Repligen Corporation $RGEN - MarketBeat
Repligen (NASDAQ:RGEN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Shares Down 3.09% on Feb 27 - GuruFocus
Oversold Conditions For Repligen (RGEN) - Nasdaq
Decoding Repligen Corp (RGEN): A Strategic SWOT Insight - GuruFocus
Repligen (NASDAQ: RGEN) maps 2025 bioprocessing market, debt and control risks - Stock Titan
A Glimpse Into The Expert Outlook On Repligen Through 6 Analysts - Benzinga
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Barclays Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price - MarketBeat
Barclays Adjusts Repligen (RGEN) Target Price Amid Overweight Ra - GuruFocus
Wells Fargo Lowers Price Target for RGEN, Maintains Overweight R - GuruFocus
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Repligen (NASDAQ:RGEN) Price Target Lowered to $180.00 at Wells Fargo & Company - MarketBeat
Evercore ISI Group Lowers Price Target for Repligen (RGEN) to $1 - GuruFocus
KeyBanc reiterates Repligen stock rating on product momentum - Investing.com
How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products - Yahoo Finance
Repligen (RGEN) Return To Profitability Tests Bullish Growth Narrative In Q4 2025 Results - simplywall.st
Repligen Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Or - GuruFocus
Repligen earnings beat by $0.05, revenue topped estimates By Investing.com - Investing.com South Africa
Repligen Q4 Earnings Call Highlights - Yahoo Finance
Repligen Q4 2025 Earnings Beat Estimates, Provides 2026 OutlookNews and Statistics - IndexBox
Earnings call transcript: Repligen Q4 2025 earnings surpass expectations - Investing.com
Earnings call transcript: Repligen Q4 2025 earnings surpass expectations By Investing.com - Investing.com Canada
Repligen Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance - MarketBeat
Repligen (RGEN) Beats Q4 Revenue Expectations with Strong Organi - GuruFocus
Repligen Corp (NASDAQ:RGEN) Stock Falls Despite Q4 Earnings Beat as 2026 Guidance Disappoints - ChartMill
Repligen earnings beat by $0.05, revenue topped estimates - Investing.com
Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations - Finviz
Repligen: Fourth Quarter Earnings Overview - Bitget
REPLIGEN ($RGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Repligen beats Q4 estimates but guides below consensus for 2026 - Investing.com
Repligen: Q4 Earnings Snapshot - marketscreener.com
Repligen Q4 Earnings Report: What Investors Need to Know - Benzinga
Repligen Corporation Reports Q4 and Full Year 2025 Financial Results - TradingView
Earnings Flash (RGEN) Repligen Corporation Reports Q4 Revenue $197.9M, vs. FactSet Est of $192.9M - marketscreener.com
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repligen Corp Stock (RGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MUIR GLENN P | Director |
Dec 16 '25 |
Option Exercise |
26.12 |
3,366 |
87,920 |
36,622 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):